SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Yeung brings extensive...
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Ambrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or...
• 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU
• Multiple Global Phase...
SAN DIEGO, November 9, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed...
Sino Biopharma receives exclusive rights to develop and commercialize two Ambrx enabled drug products in China Ambrx receives upfront payment plus undisclosed milestone payments and royalties.
SAN DIEGO, USA and BEIJING,...